Ligand Pharmaceuticals Incorporated
HealthcareNASDAQ:LGND · NASDAQ Global Market
+$0.97 today
Vol 0.24M · Avg 0.22M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
12.2%
avg 19.5%
ROIC
2.4%
avg 7.0%
ROA
8.0%
avg 10.7%
Analysis
ROE is currently the strongest return metric at 12.2% versus its period average of 19.5%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Todd C. Davis | Chief Executive Officer & Director | $1.51M | — | 65 | $199,381.00 | 0.99% |
Octavio Espinoza | Chief Financial Officer | $895,518.00 | — | 55 | $0.00 | <0.01% |
Andrew T. Reardon | Chief Legal Officer & Secretary | $758,766.00 | — | 51 | $46,382.00 | 0.23% |
Melanie J. Herman | Executive Director of Investor Relations and Financial Planning & Analysis | $275,099.00 | — | 47 | — | — |
Karen R. Reeves | Senior Vice President of Investments & Head of Clinical Strategy | — | — | 76 | $1,161.00 | <0.01% |
Keith Marschke | Senior Vice President of Biology & Scientific Affairs | — | — | — | — | — |
Vincent D. Antle | Senior Vice President of Technical Operations & QA - Capitsol | — | — | 57 | — | — |
Patrick Lucy | Senior Vice President & CBO Protein Expression Business | — | — | — | — | — |
Paul J. Hadden | Senior Vice President of Investments & Business Development | — | — | — | — | — |
Richard Baxter | Senior VP of Investment Operations | — | — | 63 | — | — |
Scott Plesha | Chief Executive Officer of Pelthos Therapeutics | — | — | 61 | — | — |
Lauren Hay | Vice President of Strategic Planning & Investment Analytics | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
106
$15.77M
Net Sentiment
$15.77M
Net selling
Most Active
KOZARICH JOHN W
48 transactions
1–10 of 106
Analysis
Insiders reported 0 buys worth $0.00 and 106 sells worth $15.77M over the last 12 months. That adds up to net selling of $15.77M. KOZARICH JOHN W was the most active insider with 48 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +2.2% (15yr)2 analysts |
| Revenue | N/A | N/A | +31.8% | +13.9% (15yr)2 analysts |
| Net Income | N/A | N/A | N/A | +1.8% (15yr)2 analysts |
| EBIT | N/A | N/A | +262.4% | +13.0% (15yr)2 analysts |
Analysis
Recent growth has been strongest in EBIT at +262.4% over three years. Forward estimates point to Revenue at +13.9% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
$5.64B
Belite Bio, Inc
NASDAQ:BLTE
$5.54B
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
$4.99B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.63B
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$3.61B
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMS
$3.55B
Viking Therapeutics, Inc.
NASDAQ:VKTX
$3.34B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.01B
Soleno Therapeutics, Inc.
SLNO
$2.76B
ADMA Biologics, Inc.
NASDAQ:ADMA
$1.90B
Who manages LGND?
Ligand Pharmaceuticals Incorporated (LGND) lists 12 active executives. The top listed executive is Karen R. Reeves, Senior Vice President of Investments & Head of Clinical Strategy.
Are LGND insiders buying or selling?
Recent insider activity shows net selling of $2.20M.
Explore More
Continue the stock analysis
Jump to another research area for this company.